Viyash Scientific Limited has announced its financial results for the second quarter of fiscal year 2027. The company reported a 16.2% year-over-year increase in revenue from operations, reaching ₹9,879 million. EBITDA saw a 10.3% rise to ₹2,077 million, and Profit After Tax (PAT) grew by 16.1% to ₹847 million. The results reflect the company’s continued expansion and strategic investments.
Viyash Scientific Announces Strong Q2 FY27 Financial Performance
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has declared its financial results for the quarter ended September 30, 2026. The integrated pharmaceutical company demonstrated robust growth, with revenue from operations climbing to ₹9,879 million, a significant increase of 16.2% compared to the same period last year (Q2 FY26). This performance underscores the company’s expanding market presence and effective business strategies.
Key Financial Highlights
The company’s operational efficiency is reflected in its EBITDA, which rose by 10.3% year-over-year to ₹2,077 million in Q2 FY27. The EBITDA margin stood at 21.0%. Profit After Tax (PAT) for the quarter surged by 16.1% to ₹847 million, indicating improved profitability. On a consolidated basis, the first half of FY27 (H1 FY27) also showed strong momentum, with revenue from operations up by 17.8% to ₹19,343 million and PAT increasing by an impressive 49.4% to ₹1,639 million.
Strategic Growth and Outlook
Dr. Hari Babu Bodepudi, Managing Director and Group CEO of Viyash Scientific, commented on the company’s performance, highlighting the stellar quarter with H1 revenue up 17.8% and H1 PAT at INR 164 Cr, up ~50% from last year. The acquisition of BioForLife in Italy is noted as a significant step in strengthening the companion animal platform. The company is also actively investing in new oncology capabilities, an in-house companion animal manufacturing facility, and expanding its API capacity to meet growing customer demand. The focus remains on disciplined execution, R&D-led growth, and sustainable value creation.
Consolidated Financial Snapshot (in millions)
Q2 FY27 vs Q2 FY26
- Revenue from operations: ₹9,879 (up 16.2% YoY)
- EBITDA: ₹2,077 (up 10.3% YoY)
- EBITDA %: 21.0%
- Profit after tax (PAT): ₹847 (up 16.1% YoY)
H1 FY27 vs H1 FY26
- Revenue from operations: ₹19,343 (up 17.8% YoY)
- EBITDA: ₹4,124 (up 29.9% YoY)
- EBITDA %: 21.3%
- Profit after tax (PAT): ₹1,639 (up 49.4% YoY)
Source: BSE
